ClinicalTrials.gg
TerminatedNCT02415062CUPIDUpdated Nov 10, 2026

The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With Dementia

A Phase 2 interventional study of Donepezil in Parkinson's Disease, sponsored by Inje University. Terminated at 1 site in South Korea. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Inje University · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
We cannot enroll the participants
Updated Nov 10, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing donepezil in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. Donepezil · Parkinson Disease.

Enrollment
10th of 12
10 · median 22
Started
2015
with 1 other
Phase 2
6 of 13
1 open now
Registered
7th of 13
by date
Lead sponsor
1 of 13
Inje University

Among the 13 studies testing donepezil in Parkinson Disease, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2015, is one of 6 in phase 2, and was the 7th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 13 studies testing donepezil in Parkinson Disease is open now. Recruiting first, the newest first:

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing donepezil in Parkinson Disease, or all of them as a file.
02

Study summary

The purpose of this study to evaluate the safety and efficacy of high-dose donepezil (23mg) in Parkinson's disease with dementia compared to standard dose donepezil.

Read the detailed description

This study is open-label, prospective, randomized paralleled study. The investigators evaluate the efficacy of high-dose donepezil in patients with Parkinson's disease with dementia (PDD) who have taken standard donepezil (10mg) for 12 weeks. The participants, who sign the informed consent, are assigned into two groups randomly (high-dose donepezil group and standard donepezil group). All participants will be maintained the medication for 24 weeks and assessed cognitive function at 24 weeks. They will visit to clinic for 3 times (4, 12, 24 weeks) to assess cognitive function and adverse event. After the end of study, all participants were administrated by standard dose donepezil again.

03

Conditions studied

  • Parkinson's Disease

Keywords

  • Parkinson's disease
  • dementia
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed as Parkinson's disease according to Queen Brain Bank criteria
  • Patients who have been diagnosed as dementia after diagnosing Parkinson's disease at least 1 year.
  • Patients with Hoehn and Yahr staging from 2 to 4
  • Patients with score from 10 to 24
  • Patients who have taken donepezil for at least 12 weeks before screening period
  • Patients whose medications for Parkinson's disease have not change for 1 month
  • Patients who give

Exclusion criteria

Exclusion criteria :

  • Patients who cannot be performed neuropsychiatric test because of hearing and visual difficulty
  • Patients who have taken medicine affecting cognitive function such as anticholinergic drug and memantine -Patients diagnosed as dementia with Lewy body and vascular dementia-
  • Patients who have history of neurosyphilis, head trauma, encephalitis or other movement disorders
  • Patients who have psychiatric disease
  • Except patients who are stable state under antidepressant or atypical neuroleptics
  • Patients with child-bearing periods
  • Patients who have severe liver or kidney disease necessary for aggressive treatment
  • Patients who have gastrointestinal disease needed for treatment
  • Patients who cannot taken tablet per oral
  • Patients who are participated in other clinical trial except observational study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    high dose donepezil (23mg)

    Patients with dementia in Parkinson's disease, who are treated with high dose donepezil (23mg)

    Drug: Donepezil

  • Active comparator
    standard dose denepezil (10mg)

    Patients with dementia in Parkinson's disease, who are treated with standard dose donepezil (10mg)

    Drug: Donepezil

Interventions

  • 23mg/day for 24 weeks versus 10mg/day for 24 weeks

    Also known as: aricept

06

What researchers measure

Primary outcomes

  1. Korean Mini-Mental State Examination-2 (MMSE-2)

    scale for general cognitive function, We used Korean version of MMSE-2 from PAR company

    Time frame: 24 weeks

Secondary outcomes

  1. Korean-Instrumental Activities of Daily Living

    scales for activities daily living

    Time frame: 24 weeks

  2. Clinical dementia rating

    scales for activities of daily living

    Time frame: 24 weeks

  3. Unified Parkinson's disease rating scale (UPDRS) part 3

    scales for motor symptoms in Parkinson's disease

    Time frame: 24 weeks

  4. Modified Hoehn & Yahr stage

    scales for status of Parkinson's disease

    Time frame: 24 weeks

  5. Schwab & England Activities of Daily Living

    scales for activities daily living

    Time frame: 24 weeks

  6. Caregiver-Administered Neuropsychiatric Inventory

    scales for status of caregiver

    Time frame: 24 weeks

  7. Global Deterioration Scale

    scales for activities of daily living

    Time frame: 24 weeks

  8. Korean-Montreal Cognitive Assessment

    scales for cognition

    Time frame: 24 weeks

  9. Semantic fluency to evaluate neuropsychiatric symptoms

    scales for language

    Time frame: 24 weeks

07

Study locations

1 site
  • Inje university, busan paik hospital
    Busan, South Korea
08

References and documents

Publications

  • Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005 Jul;76(7):934-9. doi: 10.1136/jnnp.2004.050682. PubMed 15965198 ↗
  • Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry. 2004 Jan;19(1):1-8. doi: 10.1002/gps.993. PubMed 14716693 ↗
  • Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):708-12. doi: 10.1136/jnnp.72.6.708. PubMed 12023410 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Jul 2015, a primary completion of Dec 2016 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2016 → Dec 2016 and completion Dec 2017 → Jun 2017.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2015
First posted
Apr 14, 2015
Start
Jul 2015
Primary completionActual
Dec 2016was Oct 2016
CompletionActual
Jun 2017was Dec 2017
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated We cannot enroll the participants
changed Nov 10, 2026
Primary completion
Oct 2016→Dec 2016 (actual)
Nov 10, 2026
Study completion
Dec 2017→Jun 2017 (actual)
Nov 10, 2026
Enrollment
150 (estimated)→10 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Status unknown→Terminated
    Why stopped We cannot enroll the participants
    Primary completion Oct 2016→Dec 2016 (now actual)
    Study completion Dec 2017→Jun 2017 (now actual)
    Enrollment 150 (estimated)→10 (actual)
    + 6 other changes: verification date, design details, contact details, site details, references and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02415062
Lead sponsor
Inje University
Responsible party
Sangjin Kim (Busan Paik Hospital, Inje University, Inje University) — Principal investigator
First posted
Apr 14, 2015
Start date
Jul 2015
Primary completion
Dec 2016
Completion
Jun 2017
Last update
Nov 10, 2026

Study contacts

Sangjin Kim, Professor
principal investigator · Inje University Haeundae Paik Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion